Maxcyte (MXCT) Non-Current Deferred Tax Liability (2024 - 2025)
Maxcyte's (MXCT) quarterly Non-Current Deferred Tax Liability came in at $1.0 million in Q4 2025, down 18.48% year-over-year from $1.2 million in Q4 2024, and down 18.48% quarter-over-quarter from $1.2 million in Q4 2024.
Powered by 
Analysis
Maxcyte (MXCT) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Maxcyte (MXCT) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $1.0 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 18.48% year-over-year to $1.0 million in Q4 2025; TTM through Dec 2025 was $1.0 million, a 18.48% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 18.48% from the prior year.
- Non-Current Deferred Tax Liability was $1.0 million for Q4 2025 at Maxcyte, down from $1.2 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $1.2 million in Q4 2024 and troughed at $1.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.48 Bn | 221.41 Bn | 8.34 Bn |
| 2 | Danaher | 144.42 Bn | 140.08 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 40.86 Bn | 39.11 Bn | 1.04 Bn |
| 4 | Illumina | 30.97 Bn | 29.80 Bn | 770.00 Mn |
| 5 | Revvity | 13.85 Bn | 12.83 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.27 Bn | 11.01 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn |
| 8 | Repligen | 9.33 Bn | 8.31 Bn | 110.04 Mn |
| 9 | 10x Genomics | 8.77 Bn | 8.21 Bn | 112.50 Mn |
| 10 | Maxcyte | 131.93 Mn | 131.93 Mn | 5.60 Mn |